Holen Sie sich die Stockscreener-App
0.7554
0.09%
-0.0007
Schlusskurs vom Vortag:
$0.7561
Offen:
$0.7474
24-Stunden-Volumen:
422.50K
Relative Volume:
0.55
Marktkapitalisierung:
$37.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-0.6456
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
-10.12%
1M Leistung:
-22.12%
6M Leistung:
-52.19%
1J Leistung:
-65.66%
1-Tages-Spanne:
$0.7406
$0.79
1-Wochen-Bereich:
$0.7293
$0.845
52-Wochen-Spanne:
$0.7293
$2.46
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Vergleichen Sie PDSB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.7554 | 41.37M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsInflation Watch & Safe Entry Point Identification - newser.com
It makes sense and dollars to buy PDS Biotechnology Corporation (PDSB) stock - Setenews
Is PDS Biotechnology Corporation stock entering bullish territoryJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
PDS Biotechnology Corp (EU6.DU) stock price, news, quote and history - Yahoo Finance Singapore
Tools to assess PDS Biotechnology Corporation’s risk profilePortfolio Performance Report & Consistent Return Investment Signals - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2025 Earnings Call Transcript - Insider Monkey
Will PDS Biotechnology Corporation stock go up soonWeekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Long-Term Safe Return Strategies - newser.com
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology: Promising Trial Results and Financial Update - TipRanks
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 - Investing.com UK
HC Wainwright & Co. Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Q3 2025 Earnings Report - MarketBeat
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 By Investing.com - Investing.com South Africa
PDS Biotechnology Trims Losses And Aims For Accelerated Drug Approval - Finimize
PDS Biotechnology Corporation (PDSB) Q3 FY2025 earnings call transcript - Yahoo Finance
PDS biotechnology Q3 net loss narrows on lower operating expenses - MarketScreener
PDS Biotechnology Corporation Completes VERSATILE-002 Phase 2 Trial, Pursues Expedited Approval for HPV16-Positive Head and Neck Cancer Treatment - Quiver Quantitative
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - The Manila Times
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[8-K] PDS Biotechnology Corp Reports Material Event | PDSB SEC FilingForm 8-K - Stock Titan
PDS Biotech (Nasdaq: PDSB) to seek accelerated approval in VERSATILE-003 on 6.3-month PFS - Stock Titan
PDS Biotechnology Announces $11.1M Securities Purchase Agreement - TipRanks
PDS Biotech raises $5.3 million in registered direct offering By Investing.com - Investing.com Canada
PDS Biotechnology announces up to $11.1 million registered direct offering - MarketScreener
PDS Biotech raises $5.3 million in registered direct offering - Investing.com India
PDS Biotechnology Corporation Announces $5.3 Million Securities Offering to Support Ongoing Clinical Trials - Quiver Quantitative
PDS Biotechnology stock falls after $5.3 million registered direct offering By Investing.com - Investing.com Australia
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):